Entropy Technologies LP acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,067 shares of the company’s stock, valued at approximately $669,000.
Several other institutional investors and hedge funds have also bought and sold shares of CRSP. Mcguire Capital Advisors Inc. purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at about $25,000. Ramirez Asset Management Inc. purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth approximately $26,000. Rothschild Investment LLC boosted its holdings in shares of CRISPR Therapeutics by 836.7% in the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after buying an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in shares of CRISPR Therapeutics by 196.9% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after buying an additional 382 shares during the last quarter. Finally, Oakworth Capital Inc. bought a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $34,000. 69.20% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. This trade represents a 16.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on CRSP
CRISPR Therapeutics Trading Up 0.2%
Shares of NASDAQ:CRSP opened at $47.64 on Thursday. The stock has a 50 day moving average of $52.60 and a 200 day moving average of $52.49. The company has a market cap of $4.59 billion, a PE ratio of -7.66 and a beta of 1.71. CRISPR Therapeutics AG has a 12-month low of $44.12 and a 12-month high of $78.48. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The firm had revenue of $1.46 million for the quarter. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -4.9 EPS for the current year.
About CRISPR Therapeutics
CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.
Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.
Read More
- Five stocks we like better than CRISPR Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
